Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978677 | 1.00 | NAAA (0.53) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19978675 | 1.00 | NAAA (0.53) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19978763 | 0.98 | NAAA (0.50) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19978761 | 0.98 | NAAA (0.50) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19979040 | 0.92 | ALDH1A1 (0.52) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19979041 | 0.92 | ALDH1A1 (0.52) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL4248770 | 0.83 | NAAA (0.57) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL987073 | 0.83 | NAAA (0.57) | NAAAEPHX1FAAHTSHRZDHHC7 | |
| SCHEMBL19978742 | 0.83 | — | — | |
| SCHEMBL19978743 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | NAAA 196/4885EPHX1 2194/4885FAAH 3055/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | NAAA 196/4885EPHX1 2194/4885FAAH 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.